Indications
Each indication opens its study.
CNS & addiction
Stage of development
-
PNB-091
Cocaine AddictionPan-CCK blocker
- Molecule
- PNB-091
- Indication
- Cocaine Addiction
- Biological action
- Pan-CCK blocker
- Status
- IND ready
- Target and mechanism
- Pan (dual) CCK antagonist with dopamine-pathway modulation.
- Key findings
Active in anxiety and depression models (X-maze, black/white box, swim test). Locomotion studies, cocaine substitution and antagonism models were run in collaboration with NIDA.
Prevention of addiction was shown in intracranial self-stimulation assays in rats.
- Development
Two-step synthesis, purity above 99.7%; stable in rat, dog and human liver microsomes. ICH toxicology studies are to be launched.
- Intellectual property
- Patents filed in the US, Europe and rest of world; USPTO patent issued 28 December 2014.
Interested in a programme?
PNB Vesper welcomes discussions on clinical development, licensing, co-development and investment for any molecule in the pipeline.
